Difference between revisions of "Quizartinib (Vanflyta)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 5: Line 5:
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 
===[[Acute_myeloid_leukemia,_FLT3-positive|FLT3+ AML]]===
 
===[[Acute_myeloid_leukemia,_FLT3-positive|FLT3+ AML]]===
−
# '''CP0001:''' Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10;31(29):3681-7. Epub 2013 Sep 3. [https://doi.org/10.1200/jco.2013.48.8783 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3804291/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/24002496 PubMed] NCT00462761
 
−
<!--
 
−
# '''Abstract:''' Jorge E. Cortes, Alexander E Perl, Hervé Dombret, Sabine Kayser, Björn Steffen, Philippe Rousselot, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Guy Gammon, Denise Trone, Eugen Leo, and Mark J. Levis Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 48. [http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/48 link to abstract] -->
 
−
# '''ACE:''' Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):889-903. Epub 2018 May 31. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30240-7/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/29859851 PubMed] NCT00989261
 
−
# '''2689-CL-2004:''' Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood. 2018 Aug 9;132(6):598-607. Epub 2018 Jun 6. [http://www.bloodjournal.org/content/132/6/598.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6085992/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29875101 PubMed] NCT01565668
 
−
# '''QuANTUM-R:''' Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):984-997. Epub 2019 Jun 4. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30150-0/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/31175001 PubMed] NCT02039726
 
  
 
==Also known as==
 
==Also known as==

Revision as of 18:26, 30 August 2022

Note: this drug is only approved in Japan, at this time.

Mechanism of action

FLT3 inhibitor

Diseases for which it is used

FLT3+ AML

Also known as

  • Code names: AC220, ASP2689
  • Brand name: Vanflyta
Retrieved from "https://hemonc.org/w/index.php?title=Quizartinib_(Vanflyta)&oldid=59513"